CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eutropics, Inc, (Cambridge, MA) and Tolero Pharmaceuticals, Inc, (Lehi, UT) announced today that clinical study results demonstrating a predictive biomarker for Chronic Lymphocytic Leukemia (CLL) patient response to treatment with Toleros’ experimental drug alvocidib were published in the medical journal Leukemia. The results appear in an article entitled, “Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.” The study, performed in collaboration with Ohio State University and Duke University Medical Centers, compared a novel algorithm readout of Eutropics’ companion diagnostic platform, Praedicare Dx, to positive patient outcome after alvocidib treatment. Importantly, a different algorithm readout of Praedicare Dx was discovered that predicts likelihood of adverse effects, providing further guidance for treatment.
Help employers find you! Check out all the jobs and post your resume.
